Edit
Bizwit-Logo-Final

Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. We have a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. 

Global Acute Myeloid Leukemia Market to reach USD XX billion by the end of 2030

Global Acute Myeloid Leukemia Market Size Study & Forecast, By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Other Chemotherapies), and Regional Analysis, 2023-2030

Product Code: HLSDT-22589363
Publish Date: 20-05-2023
Page: 200

Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.

In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC’s ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.

Major market players included in this report are:
Novartis AG
Genmab AS
Otsuka Holdings Co. Ltd
Sanofi-Aventis (Genzyme Corporation)
Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sunesis Pharmaceuticals Inc.
Astellas Pharma Inc.
Oncolyze Inc.

Recent Developments in the Market:
Ø In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
Ø In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.

Global Acute Myeloid Leukemia Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Chemotherapy, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Chemotherapy:
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Other Chemotherapies
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Acute Myeloid Leukemia Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Acute Myeloid Leukemia Market Dynamics
3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of acute myeloid leukemia
3.1.1.2. Rising geriatric population
3.1.2. Market Challenges
3.1.2.1. Stringent regulations on drugs
3.1.2.2. Complications related to chemotherapy
3.1.3. Market Opportunities
3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
3.1.3.2. Increasing investments in research and development
Chapter 4. Global Acute Myeloid Leukemia Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Acute Myeloid Leukemia Market, by Chemotherapy
5.1. Market Snapshot
5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance – Potential Analysis
5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
5.4.1. Cytarabine
5.4.2. Anthracycline Drugs
5.4.3. Alkylating Agents
5.4.4. Anti-metabolites
5.4.5. Tyrosine Kinase Inhibitors
5.4.6. Hormonal Therapy
5.4.7. Other Chemotherapies
Chapter 6. Global Acute Myeloid Leukemia Market, Regional Analysis
6.1. Top Leading Countries
6.2. Top Emerging Countries
6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
6.4. North America Acute Myeloid Leukemia Market
6.4.1. U.S. Acute Myeloid Leukemia Market
6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
6.4.2. Canada Acute Myeloid Leukemia Market
6.5. Europe Acute Myeloid Leukemia Market Snapshot
6.5.1. U.K. Acute Myeloid Leukemia Market
6.5.2. Germany Acute Myeloid Leukemia Market
6.5.3. France Acute Myeloid Leukemia Market
6.5.4. Spain Acute Myeloid Leukemia Market
6.5.5. Italy Acute Myeloid Leukemia Market
6.5.6. Rest of Europe Acute Myeloid Leukemia Market
6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
6.6.1. China Acute Myeloid Leukemia Market
6.6.2. India Acute Myeloid Leukemia Market
6.6.3. Japan Acute Myeloid Leukemia Market
6.6.4. Australia Acute Myeloid Leukemia Market
6.6.5. South Korea Acute Myeloid Leukemia Market
6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
6.7. Latin America Acute Myeloid Leukemia Market Snapshot
6.7.1. Brazil Acute Myeloid Leukemia Market
6.7.2. Mexico Acute Myeloid Leukemia Market
6.8. Middle East & Africa Acute Myeloid Leukemia Market
6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
6.8.2. South Africa Acute Myeloid Leukemia Market
6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market

Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Novartis AG
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Recent Developments
7.3.2. Genmab AS
7.3.3. Otsuka Holdings Co. Ltd
7.3.4. Sanofi-Aventis (Genzyme Corporation)
7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.3.6. Pfizer Inc.
7.3.7. F. Hoffmann-La Roche Ltd
7.3.8. Sunesis Pharmaceuticals Inc.
7.3.9. Astellas Pharma Inc.
7.3.10. Oncolyze Inc.
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption

At Bizwit Research and Consultancy, we employ a thorough and iterative research methodology with the goal of minimizing discrepancies, ensuring the provision of highly accurate estimates and predictions over the forecast period. Our approach involves a combination of bottom-up and top-down strategies to effectively segment and estimate quantitative aspects of the market, utilizing our proprietary data & AI tools. Our Proprietary Tools allow us for the creation of customized models specific to the research objectives. This enables us to develop tailored statistical models and forecasting algorithms to estimate market trends, future growth, or consumer behavior. The customization enhances the accuracy and relevance of the research findings.
We are dedicated to clearly communicating the purpose and objectives of each research project in the final deliverables. Our process begins by identifying the specific problem or challenge our client wishes to address, and from there, we establish precise research questions that need to be answered. To gain a comprehensive understanding of the subject matter and identify the most relevant trends and best practices, we conduct an extensive review of existing literature, industry reports, case studies, and pertinent academic research.
Critical elements of methodology employed for all our studies include:
Data Collection:
To determine the appropriate methods of data collection based on the research objectives, we consider both primary and secondary sources. Primary data collection involves gathering information directly from various industry experts in core and related fields, original equipment manufacturers (OEMs), vendors, suppliers, technology developers, alliances, and organizations. These sources encompass all segments of the value chain within the specific industry. Through in-depth interviews, we engage with key industry participants, subject-matter experts, C-level executives of major market players, industry consultants, and other relevant experts. This allows us to obtain and validate critical qualitative and quantitative information while evaluating market prospects. AI and Big Data are instrumental in our primary research, providing us with powerful tools to collect, analyze, and derive insights from data efficiently. These technologies contribute to the advancement of research methodologies, enabling us to make data-driven decisions and uncover valuable findings.
In addition to primary sources, we extensively utilize secondary sources to enhance our research. These include directories, databases, journals focusing on related industries, company newsletters, and information portals such as Bloomberg, D&B Hoovers, and Factiva. These secondary sources enable us to identify and gather valuable information for our comprehensive, technical, market-oriented, and commercial study of the market. Additionally, we utilize AI algorithms to automate the collection of vast amounts of data from various sources such as surveys, social media platforms, online transactions, and web scraping. And employ Big Data technologies for storage and processing of large datasets, ensuring that no valuable information is missed during the data collection process.
Data Analysis:
Our team of experts carefully examine the gathered data using suitable statistical techniques and qualitative analysis methods. For quantitative analysis, we employ descriptive statistics, regression analysis, and other advanced statistical methods, depending on the characteristics of the data. This analysis may also incorporate the utilization of AI tools and big data analysis techniques to extract meaningful insights.
To ensure the accuracy and reliability of our findings, we extensively leverage data science techniques, which help us minimize discrepancies and uncertainties in our analysis. We employ Data Science to clean and preprocess the data, ensuring its quality and reliability. This involves handling missing data, removing outliers, standardizing variables, and transforming data into suitable formats for analysis. The application of data science techniques enhances our accuracy, efficiency, and depth of analysis, enabling us to stay competitive in dynamic market environments.
Market Size Estimation:
Our proprietary data tools play a crucial role in deriving our market estimates and forecasts. Each study involves the creation of a unique and customized model. The model incorporates the gathered information on market dynamics, technology landscape, application development, and pricing trends. AI techniques, such as machine learning and deep learning, aid us to analyze patterns within the data to identify correlations, trends, and relationships. By recognizing patterns in consumer behavior, purchasing habits, or market dynamics, our AI algorithms aid us in more precise estimations of market size. These factors are simultaneously analyzed within the model, allowing for a comprehensive assessment. To quantify their impact over the forecast period, correlation, regression, and time series analysis are employed.
To estimate and validate the market size, we employ both top-down and bottom-up approaches. The preference is given to a bottom-up approach, where key regional markets are analyzed as separate entities. This data is then integrated to obtain global estimates. This approach is crucial as it provides a deep understanding of the industry and helps minimize errors.
In our forecasting process, we consider various parameters such as economic tools, technological analysis, industry experience, and domain expertise. By taking all these factors into account, we strive to produce accurate and reliable market forecasts. When forecasting, we take into consideration several parameters, which include:
Market driving trends and favorable economic conditions
Restraints and challenges that are expected to be encountered during the forecast period.
Anticipated opportunities for growth and development
Technological advancements and projected developments in the market
Consumer spending trends and dynamics
Shifts in consumer preferences and behaviors.
The current state of raw materials and trends in supply versus pricing
Regulatory landscape and expected changes or developments.
The existing capacity in the market and any expected additions or expansions up to the end of the forecast period.
To assess the market impact of these parameters, we assign weights to each one and utilize weighted average analysis. This process allows us to quantify their influence on the market and derive an expected growth rate for the forecasted period. By considering these various factors and applying a weighted analysis approach, we strive to provide accurate and reliable market forecasts.
Insight Generation & Report Presentation:
After conducting the research, our experts analyze the findings in relation to the research objectives and the specific needs of the client. They generate valuable insights and recommendations that directly address the client’s business challenges. These insights are carefully connected to the research findings to provide a comprehensive understanding.
Next, we create a well-structured research report that effectively communicates the research findings, insights, and recommendations to the client. To enhance clarity and comprehension, we utilize visual aids such as charts, graphs, and tables. These visual elements are employed to present the data in an engaging and easily understandable format, ensuring that the information is accessible and visually appealing to the client. Our aim is to deliver a clear and concise report that conveys the research findings effectively and provides actionable recommendations to meet the client’s specific needs.

Need Assistance

Contact Person -
Krishant Mennon
Call us @
+ 91 99931 15879
Email: sales@bizwitresearch.com

Checkout

Why Choose Us?

Quality over Quantity

Backed by 60+ paid data sources our reports deliver crisp insights with no compromise quality.

Analyst Support

24x7 Chat Support plus
free analyst hours with every purchase

Flawless Methodology

Our 360-degree approach of market study, our research methods leave stones unturned.
Enquiry Now